financetom
Business
financetom
/
Business
/
Innsuites Hospitality Trust Insider Sold Shares Worth $232,812,500, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Innsuites Hospitality Trust Insider Sold Shares Worth $232,812,500, According to a Recent SEC Filing
Oct 17, 2025 3:13 PM

05:35 PM EDT, 10/17/2025 (MT Newswires) -- James F Wirth, 10% Owner, President & CEO, on October 16, 2025, sold 12,500 shares in Innsuites Hospitality Trust ( IHT ) for $232,812,500. Following the Form 4 filing with the SEC, Wirth has control over a total of 6,159,296 shares of the company, with 6,159,296 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/82473/000149315225018526/xslF345X05/ownership.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
Aug 9, 2024
On Friday, the FDA approved ARS Pharmaceuticals Inc’s neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients. ARS Pharma’s Neffy is to be an alternative to EpiPen and other autoinjectors like Sanofi SA’s  Auvi-Q filled with epinephrine. The approval comes almost two months before the PDUFA...
ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions
ARS Pharmaceuticals' Neffy Nasal Spray Approved by FDA for Type I Allergic Reactions
Aug 9, 2024
01:42 PM EDT, 08/09/2024 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Friday that the US Food and Drug Administration has approved neffy 2 mg, an epinephrine nasal spray, to treat Type I allergic reactions, including anaphylaxis, in adults and children weighing at least 30 kilograms. In a statement, the FDA said neffy is the first approved epinephrine product...
Turtle Beach Positioned for Growth Amid New Gaming Accessory Cycle, Oppenheimer Says
Turtle Beach Positioned for Growth Amid New Gaming Accessory Cycle, Oppenheimer Says
Aug 9, 2024
01:43 PM EDT, 08/09/2024 (MT Newswires) -- Turtle Beach ( HEAR ) is set for share gains and profitable growth as it enters a new gaming accessory cycle, Oppenheimer said in a note Friday. The company posted Q2 revenue of $76.5 million and adjusted earnings before interest, taxes, depreciation and amortization of $3 million, versus the consensus of $70.7 million...
Blink Charging Q2 Earnings: Revenue Miss, EPS Miss, Lowered Guidance  Following 'Short-Term Softening Of EV Demand' (CORRECTED)
Blink Charging Q2 Earnings: Revenue Miss, EPS Miss, Lowered Guidance Following 'Short-Term Softening Of EV Demand' (CORRECTED)
Aug 9, 2024
Editor’s note: This story has been updated to correct Blink Charging’s second-quarter adjusted earnings per share figure to a loss of 18 cents. Benzinga apologizes for the error. Blink Charging Co ( BLNK ) reported its second-quarter financial results Wednesday after the bell. Here’s a rundown of the print. Q2 Earnings: Blink reported second-quarter revenue of $33.26 million, missing analyst...
Copyright 2023-2026 - www.financetom.com All Rights Reserved